LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.05) by 25.71 percent. This is a 149.06 percent decrease over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $1.901 million which beat the analyst consensus estimate of $1.759 million by 8.08 percent.